Introduction {#s1}
============

Most patients with hypertension (HTN) require two or more drugs to achieve their target blood pressure (BP) \[[@R01]\]. In fact, large-scale clinical trials have shown that thiazide diuretics and/or calcium channel blockers (CCBs) are frequently needed in addition to angiotensin II type 1 receptor blockers (ARBs) to achieve adequate BP control \[[@R02]\]. Although various guidelines recommend the use of combinations of ARBs and CCBs or diuretics \[[@R03], [@R04]\], we use three kinds of anti-hypertensive drugs when two drugs do not provide a significant reduction of BP. Although approximately 15% of patients receive three drugs, there have been few reports on whether combination therapy with three drugs is superior to a combination of two drugs \[[@R05]\]. Many patients continue to show a high BP even after treatment with high-dose (H) ARB/CCB or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ), although optimal BP control is associated with remarkable clinical benefits with regard to cardiovascular and renal protection. Therefore, we analyzed whether a changeover with a switch from combination therapy with H-ARB/CCB or M-ARB/CCB/HCTZ to combination therapy with H-ARB/CCB/HTCZ can offer better efficacy and safety in patients with HTN.

Methods {#s2}
=======

Study design {#s2a}
------------

Thirty-two hypertensive patients who had the use of H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day) or M-ARB (losartan 50 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day) more than 1 month (average 3.9 ± 6.9 months) were enrolled. We applied a changeover with a switch from H-ARB/CCB (H-ARB/CCB group) or M-ARB/CCB/HCTZ (M-ARB/CCB/HCTZ group) to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day). We did not change the kind or dose of CCB and analyzed various parameters at baseline (0 months) and after 3 months. We excluded patients with secondary HTN, heart failure of NYHA grade III or IV, liver dysfunction, renal dysfunction (defined as a serum creatinine (Cr) level of more than 2.0 mg/dL), pregnancy, or a history of allergy to ARB, CCB or HCTZ. The target BP followed the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2009 (JSH2009) \[[@R03]\]. The protocol in this study was approved by the ethics committee of Fukuoka University Hospital, and all subjects gave their informed consent to participate.

Evaluation of clinical parameters {#s2b}
---------------------------------

Office systolic BP (SBP), diastolic BP (DBP) and pulse rate (PR) measurements were obtained at 0, 1, 2 and 3 months. Body weight (BW), blood and urinary levels of biochemical parameters were obtained at 0 and 3 months. BP was determined as the mean of two measurements obtained in an office setting by the conventional cuff method using a mercury sphygmomanometer after at least 5 min of rest. All of the blood samples were collected in the morning after the patients had fasted overnight. Data regarding serum levels of biochemical parameters, such as high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), uric acid (UA), creatinine (Cr), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), sodium (Na) and potassium (K) were collected in all patients. Body mass index (BMI) was calculated as BW (kg)/height (m)^2^.

The characteristics of the patients with regard to history of dyslipidemia (DL), diabetes mellitus (DM), hyperuricemia (HU), smoking status and medication use were obtained from medical records. Patients with LDL-C ≥ 140 mg/dL, TG ≥ 150 mg/dL, and/or HDL-C \< 40 mg/dL, or who were receiving lipid-lowering therapy, were considered to have DL. DM was defined using the Japanese Diabetes Association criteria or the use of a glucose-lowering drug. HU was defined as a serum UA level of ≥ 7.0 mg/dL or the use of uric acid-lowering drugs.

Statistical analysis {#s2c}
--------------------

Statistical analysis was performed using the Stat View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, USA) at Fukuoka University (Fukuoka, Japan). Data are presented as the mean ± standard deviation (SD). Categorical and continuous variables were compared between the groups by a Chi-square analysis and unpaired *t*-test, respectively. Changes in SBP, DBP, PR, and clinical parameters following therapy were analyzed by the paired *t*-test. A value of P \< 0.05 was considered significant.

Results {#s3}
=======

Patient characteristics in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups {#s3a}
--------------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} shows the characteristics of the 32 patients, who consisted of 16 (50 %) males. The prevalence of DL, DM and HU was 56%, 16% and 19%, respectively. There were no significant differences in these patient characteristics between the H-ARB/CCB and M-ARB/M-CCB/HTCZ groups. The percentage use of β-blocker and α-blocker was 3% and 3%, respectively ([Table 2](#T2){ref-type="table"}). There were no significant differences in medications between the groups. We did not change these medications throughout the study period.

###### Baseline Patient Characteristics in All Patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ Groups

                             All patients (n = 32)   H-ARB/CCB (n = 20)   M-ARB/CCB/HTCZ (n =12)
  -------------------------- ----------------------- -------------------- ------------------------
  Age, years                 69 ± 15                 69 ± 16              68 ± 13
  Gender (male), n (%)       16 (50)                 11 (55)              5 (42)
  Smoking, n (%)             11 (34)                 8 (40)               3 (25)
  BMI, kg/m^2^               23.9 ± 4.3              23.8 ± 4.6           24.0 ± 3.9
  WC, cm                     85.7 ± 10.2             86.1 ± 11.1          87.0 ± 8.9
  DL, n (%)                  18 (56)                 10 (50)              8 (67)
    LDL-C, mg/dL             104 ± 32                106 ± 35             100 ± 27
    HDL-C, mg/dL             52 ± 12                 51 ± 13              52 ± 10
    TG, mg/dL                145 ± 92                138 ± 92             155 ± 95
  DM, n (%)                  5 (16)                  3 (15)               2 (17)
    Fasting glucose, mg/dL   102 ± 29                102 ± 35             103 ± 16
    HbA1c, %                 5.3 ± 0.9               5.4 ± 1.0            5.2 ± 0.5
  HU, n (%)                  6 (19)                  4 (20)               2 (12)
    UA, mg/dL                5.4 ± 1.3               5.3 ± 1.2            5.7 ± 1.4
  CAD, n (%)                 4 (13)                  4 (20)               0 (0)

Continuous variables are expressed as mean ± SD. BMI: body mass index; WC: waist circumference; DL: dyslipidemia; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; DM: diabetes mellitus; HbA1c: hemoglobin A1c; HU: hyperuricemia; UA: uric acid; CAD: coronary artery disease.

###### Medications in All Patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ Groups

                                           All patients (n = 32)   H-ARB/CCB (n = 20)   M-ARB/CCB/HTCZ (n = 12)
  ---------------------------------------- ----------------------- -------------------- -------------------------
  Medication use                                                                        
    CCBs                                                                                
      Nifedipine 40 mg, n (%)              25 (78)                 14 (70)              11 (92)
      Amlodipine 5 mg, n (%)               7 (22)                  6 (30)               1 (8)
    β-blocker, n (%)                       1 (3)                   1 (5)                0 (0)
    α-blocker, n (%)                       1 (3)                   1 (5)                0 (0)
  Medication use before changeover                                                      
    ARBs, n (%)                            20 (63)                 20 (100)             0 (0)
      Telmisartan 80 mg, n (%)             12 (38)                 12 (60)              0 (0)
      Olmesartan 40 mg, n (%)              6 (19)                  6 (30)               0 (0)
      Valsartan 160 mg, n (%)              2 (6)                   2 (10)               0 (0)
    Losartan 50 mg + HCTZ 12.5 mg, n (%)   12 (38)                 0 (0)                12 (100)

CCBs: calcium channel blockers; ARBs: angiotensin II receptor blockers; HCTZ: hydrochlorothiazide.

Time courses of BP and PR in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups {#s3b}
----------------------------------------------------------------------------------------

The time courses of BP and PR are shown in [Figure 1](#F1){ref-type="fig"}. In all patients, significant reductions in SBP (142 ± 12 to 125 ± 15 mm Hg) and DBP (77 ± 13 to 69 ± 11 mm Hg), but not PR, were observed after 3 months. In the H-ARB/CCB group, SBP and DBP after 3 months were significantly lower than those at 0 months (SBP: 144 ± 12 to 124 ± 15 mm Hg, DBP: 76 ± 10 to 67 ± 10 mm Hg). In the M-ARB/CCB/HTCZ group, SBP after 3 months was significantly lower than that at 0 months (SBP: 139 ± 12 to 127 ± 15 mm Hg).

![Changes in SBP, DBP and PR in all patients (n = 32) and in the H-ARB/CCB (n = 20) and M-ARB/CCB/HCTZ (n = 12) groups. \*P \< 0.05 vs. 0 months (M).](jocmr-09-098-g001){#F1}

Percentages (%) of patients who reached the target BP at 0 and 3 months in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups {#s3c}
--------------------------------------------------------------------------------------------------------------------------------------

The % patients who reached the target BP at 3 months in all patients (72%) and in H-ARB/CCB group (80 %) was significantly higher than that at 0 months (all patients (19%) and H-ARB/CCB group (15%) ([Fig. 2](#F2){ref-type="fig"}). In addition, % patients who reached the target BP at 3 months (58%) tended to be higher than that at 0 months (25%) in the M-ARB/CCB (P \< 0.10).

![Percentages (%) of patients who reached the target BP at 0 and 3 months in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups. \*P \< 0.05 vs. 0 months.](jocmr-09-098-g002){#F2}

ΔSBP and ΔDBP in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups {#s3d}
----------------------------------------------------------------------------

Changes in SBP and DBP from 0 to 3 months (Δ = the value at 3 months minus the value at 0 months) are shown in [Figure 3](#F3){ref-type="fig"}. There were no significant differences in ΔSBP or ΔDBP among all patients or the H-ARB/CCB and M-ARB/CCB/HTCZ groups.

![ΔSBP and ΔDBP in all patients (n = 32) and in the H-ARB/CCB (n = 20) and M-ARB/CCB/HCTZ (n = 12) groups over 3 months. Δ indicates the value at 3 months minus the value at 0 months. NS: not significant.](jocmr-09-098-g003){#F3}

Changes in biochemical parameters in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups {#s3e}
------------------------------------------------------------------------------------------------

As shown in [Table 3](#T3){ref-type="table"}, there were no significant changes in biochemical parameters including Cr, BNP and the lipid profile in all patients or the H-ARB/CCB and M-ARB/CCB/HTCZ groups. On the other hand, all patients and the H-ARB/CCB group showed significantly increased serum UA, and all patients showed significantly increased serum HbA1c.

###### Biochemical Parameters at 0 and 3 Months in All Patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ Groups

                           All patients (n = 32)   H-ARB/CCB (n = 20)   M-ARB/CCB/HTCZ (n = 12)                             
  ------------------------ ----------------------- -------------------- ------------------------- ------------- ----------- -----------
  BUN, mg/dL               18 ± 11                 20 ± 12              17 ± 12                   21 ± 15       20 ± 7      19 ± 6
  Cr, mg/dL                0.9 ± 0.4               1.0 ± 0.4            0.9 ± 0.5                 1.0 ± 0.4     1.0 ± 0.4   0.9 ± 0.4
  eGFR, mL/min/1.73 m^2^   63 ± 21                 61 ± 23              67 ± 22                   63 ± 25       56 ± 18     60 ± 20
  UA, mg/dL                5.4 ± 1.3               6.0 ± 1.3\*          5.3 ± 1.2                 6.0 ± 1.3\*   5.7 ± 1.4   6.2 ± 1.3
  Na, mEq/L                141 ± 2                 140 ± 3              141 ± 2                   140 ± 3       140 ± 2     140 ± 3
  K, mEq/L                 4.0 ± 0.5               4.1 ± 0.7            4.0 ± 0.6                 4.2 ± 0.7     4.0 ± 0.4   4.1 ± 0.6
  TG, mg/dL                145 ± 92                135 ± 72             138 ± 92                  120 ± 61      155 ± 95    159 ± 84
  LDL-C, mg/dL             104 ± 32                102 ± 30             106 ± 35                  104 ± 34      127 ± 46    129 ± 31
  HDL-C, mg/dL             52 ± 12                 56 ± 16              51 ± 13                   58 ± 18       52 ± 10     52 ± 10
  FPG, mg/dL               102 ± 229               116 ± 81             102 ± 35                  122 ± 10      103 ± 16    106 ± 24
  HbA1c, %                 5.3 ± 0.9               5.5 ± 0.8\*          5.4 ± 1.0                 5.5 ± 1.0     5.2 ± 0.5   5.4 ± 0.5
  BNP, pg/mL               67 ± 92                 55 ± 72              66 ± 70                   66 ± 87       70 ± 124    36 ± 28

BUN: blood urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; UA: uric acid; Na: sodium; K: potassium; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FPG: fast plasma glucose; HbA1c: hemoglobin A1c; BNP: brain natriuretic peptide. \*P \< 0.05 vs. 0 months.

Discussion {#s4}
==========

In the present study, combination therapy with H-ARB/CCB/HTCZ induced a significant reduction of BP after patients switched from H-ARB/CCB or M-ARB/CCB/HTCZ. BP control is the best strategy for achieving remarkable clinical benefits with regard to cardiovascular and renal protection. There are two main explanations for why H-ARB/CCB/HTCZ induced a significant reduction in BP. First, 12.5 mg/day of HCTZ significantly increased plasma renin activity (PRA) \[[@R06]\]. In this study, the blockade of PRA activation by HTCZ using H-ARB (telmisartan 80 mg/day) may be stronger than that using M-ARB (losartan 50 mg/day). Second, telmisartan 80 mg/day itself had significantly greater depressor effects than losartan 50 mg/day \[[@R07]\].

In this study, combination therapy with H-ARB/CCB/HTCZ significantly increased serum UA after patients were switched from H-ARB/CCB because of the addition of HTCZ. Telmisartan in Micombi^®^BP partially activates peroxisome proliferator-activated receptor-γ \[[@R08]\], which may improve insulin sensitivity. This effect may be useful in hypertensive patients with insulin resistance or DM \[[@R09]\]. Unexpectedly, although H-ARB (telmisartan 80 mg/day)/CCB/HTCZ significantly increased serum HbA1c levels in all patients, there were no serious adverse effects in any of the patients.

Study limitations {#s4a}
-----------------

This study has three important limitations. First, the sample size was relatively small, which limits our ability to determine significance. Second, we applied a changeover with switching from H-ARB/CCB or M-ARB/CCB/HCTZ. A crossover study would have been preferable. Third, we measured BP and PR for only 3 months and did not evaluate the clinical outcome. Long-term prospective studies are needed to clarify the limitation.

Conclusions {#s4b}
-----------

Combination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP. Although serum UA and HbA1c increased after 3 months, there were no serious adverse effects in any of the patients.
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